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Recombinant Japanese encephalitis (JE) vaccine candidates based on a highly attenuated vaccinia virus (NYVAC-JEV) and
a canarypox virus (ALVAC-JEV) were evaluated for their ability to induce specific antibodies and cytotoxic T lymphocytes
(CTLs) in mice. Six- to eight-week-old male Balb/c mice that received one or two intraperitoneal inoculations with these JE
vaccine candidates at a dose of 1 1 107 PFU per mouse produced neutralizing antibody and antibodies to the envelope (E)
and nonstructural 1 (NS1) proteins as determined by radioimmunoprecipitation. Immunization with either of these vaccine
candidates also induced JE virus-specific T lymphocytes that proliferated in response to stimulation with infectious virus
and/or noninfectious viral antigens. Mice maintained detectable levels of neutralizing antibody and JE virus-specific memory
T cells for at least 6 months after immunization with NYVAC-JEV and for 4 months after immunization with ALVAC-JEV.
Cells induced to proliferate after stimulation with live virus contained specific CD8/ CTLs that lysed primary Balb/c mouse
kidney cells infected with JE virus and P815 mastocytoma cells infected with a recombinant vaccinia virus expressing the
premembrane (prM), E, and NS1 proteins. These CTLs also lysed P815 cells infected with vaccinia recombinants expressing
prM and E, and those expressing E and NS1, but did not lyse P815 cells infected with a recombinant virus expressing only
NS1, indicating that the CTLs mainly recognized E, but did not recognize NS1. These results demonstrate that both recombi-
nant JE vaccines, NYVAC-JEV and ALVAC-JEV, induce JE virus-specific antibody and CTLs in mice. q 1997 Academic Press
INTRODUCTION vaccinia virus strain (NYVAC) and a canarypox isolate
(ALVAC) (Tartaglia et al., 1992). Immunization of outbred
Japanese encephalitis (JE) virus, a member of the flavi-
mice with these candidates induced neutralizing (NEUT)
virus family, is distributed widely in South Asia (Monath,
antibodies and conferred protection against lethal chal-
1986; Shope, 1980). A formalin-inactivated JE virion prep-
lenge (Konishi et al., 1992, 1994).
aration purified from infected mouse brains is the only
A variety of experimental data have established a the-
JE vaccine currently approved for human use in most
ory that peptides processed from exogenous proteins
nations, but it is too expensive for use in some devel-
are bound to major histocompatibility complex (MHC)
oping countries. Allergic reactions caused by this vac-
class II molecules and are recognized by CD4/ T lympho-
cine are another drawback (Andersen and Ronne, 1991).
cytes, while peptides processed from endogenous pro-
Because of these concerns, molecular approaches to
teins are bound to MHC class I molecules and are recog-new and improved vaccines have been taken by different
nized by CD8/ T lymphocytes (Germain, 1993). It waslaboratories as a part of second-generation flavivirus vac-
reported that mice immunized with JE virus-infected cellscine development (Brandt, 1988). We have developed
developed cytotoxic T lymphocytes (CTLs) that were ablepoxvirus-vectored recombinant JE viruses for human use
to lyse JE virus-infected syngeneic cells (Murali-Krishna(Konishi et al., 1992, 1994) in order to address these
et al., 1994). The presence of CTLs decreased the levelsconcerns and also to apply these techniques to other
of infectious virus released from infected cells in vitro.flavivirus diseases, such as dengue, for which no vaccine
The adoptive transfer of JE virus-immune T cells pro-is available. Our vaccine candidates contain the premem-
tected mice from lethal challenge (Mathur et al., 1983).brane (prM), envelope (E), and nonstructural 1 (NS1)
These results suggested that CTLs were important ingenes of JE virus, and the vectors are a highly attenuated
protection and recovery from JE virus infections. Although
a protective role of antibodies has also been demon-
strated by passive transfer of monoclonal antibodies1 To whom correspondence and reprint requests should be ad-
dressed at Department of Medical Zoology, Kobe University School of against E (Kimura-Kuroda and Yasui, 1988; Mason et al.,
Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe 650, Japan. Fax: /81-
1989), new vaccines that can induce CTLs as well as78-371-2955. E-mail: ekon@icluna.kobe-u.ac.jp.
NEUT antibodies are expected to be more effective than2 Present address: Department of Pathology, University of Texas
Medical Branch, Galveston, TX 77555. those which can induce only antibody. The purpose of the
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present study was to determine whether these poxvirus- (Konishi et al., 1995). Briefly, culture fluid of infected C6/
36 cells containing approximately 2 1 108 PFU per millili-vectored JE vaccine candidates induce JE virus-specific T
lymphocytes including CTLs in mice and to characterize ter was used as the live antigen, and glutaraldehyde-
fixed lysate of infected Vero cells containing 4 mg of Ethese CTLs.
per milliliter was used as the fixed antigen.
Proliferative responses of spleen cells were measuredMATERIALS AND METHODS
based on the method described by Rothman et al. (1989).
Viruses
Briefly, single spleen cells were cultured with different
dilutions of each viral or control antigens at a low serumThe Nakayama strain of JE virus has been described
(Mason, 1989). NYVAC-based and ALVAC-based recom- concentration for 3 days and then at a high serum con-
centration for 2 days. The dilution of cell lysate was 1:20,binants encoding the JE virus prM, E, and NS1 genes
(abbreviated as NYVAC-JEV and ALVAC-JEV, respec- 1:200, and 1:2000, and the dilution of the live virus was
1:16, 1:64, and 1:256. The cells were then pulsed with 1tively) and their parent viruses, NYVAC and ALVAC, have
been described (Konishi et al., 1992, 1994). Viruses used mCi of tritiated ([3H]) thymidine for 16 to 20 hr before
being harvested, and [3H]thymidine incorporation wasfor infection of target cells in CTL assays were Copenha-
gen-based recombinants, vP555 encoding the prM, E, assessed by a liquid scintillation counter. Stimulation
indices were calculated by the standard formula: countsand NS1 genes of the Nakayama strain of JE virus, vP829
encoding prM and E, vP658 encoding E and NS1, and per minute (cpm) induced by the viral antigen divided by
cpm induced by the control antigen at the same dilution.vP857 encoding NS1, and their parent virus, vP410 (Koni-
shi et al., 1991). The criteria to determine positive responses were (i) a
stimulation index equal to or greater than 2.0, (ii) a signifi-
Immunization of mice and preparation of specimens cant difference between cpm induced by the viral and
control antigens as evaluated by the Student t test, andGroups of 6- to 8-week-old male Balb/c mice (Balb/
(iii) a total count per minute obtained with viral antigenscAnN; Charles River Laboratories, Portage, MI) were in-
greater than 1000 cpm. Proliferations were determinedoculated intraperitoneally (ip) with one or two doses at
to be positive when all of the three criteria were fulfilled.intervals of 2 to 3 weeks of 0.1 ml of the following immu-
nogens: 1 1 107 PFU of JEV, NYVAC-JEV, or ALVAC-JEV,
CTL assaysand their controls, phosphate-buffered saline (PBS) or 1
1 107 PFU of NYVAC or ALVAC. Two mice were used
Spleen cells (4 1 106) were stimulated by incubationper group unless otherwise stated. Blood samples were
with the live virus antigen at a final dilution of 1:8 in 2collected retro-orbitally and spleens were removed from
ml of RPMI 1640 medium containing 10% fetal bovinethese mice 3 to 6 weeks after the last inoculation. In
serum (RPMI–10% FBS) per well of 24-well microplatesexperiments for examining the duration of memory T
at 377 for 6 to 8 days. Cytotoxic activities of these cellscells, mice that had received two inoculations of vaccine
were measured by two methods: one utilizing lactatecandidates were kept 1, 2, 4, and 6 months before sample
dehydrogenase (LDH) activity and the other utilizing ra-collection. Serum samples were isolated from blood,
dioactivity as a marker of cell lysis. In the assay systempooled, and used for antibody titration. Spleens were
using LDH, these cells were washed five times with RPMIminced and passed through gauze to prepare single-cell
1640 containing 1% bovine serum albumin (RPMI– 1%suspensions. Erythrocytes contained in this suspension
BSA), resuspended in RPMI–1% BSA at different densi-were lysed by incubation with ACK lysing buffer (155 mM
ties of viable cells, and distributed in triplicate in 96-wellNH4Cl, 10 mM KHCO3 , 190 mM EDTA) for 2 min on ice.
U-bottom microplates (100 ml per well). The target cellsAfter washing, cells were used in proliferation and CTL
used for this assay were primary mouse kidney (PMK)assays.
cells prepared from kidneys of Balb/c mice. These target
cells were infected with JE or mock virus at a high m.o.i.Neutralization (NEUT) and radioimmunoprecipitation
(approximately 100 to 200 PFU/cell) 17 to 18 hr before,(RIP) tests
washed three times with RPMI–1% BSA, and distributed
Specific antibodies elicited in immunized mice were in plates (5 1 103 cells in 100 ml per well) to mix with
evaluated for NEUT and for their ability to immunoprecipi- effector cells. After plates were incubated at 377 for 6
tate 35S-labeled viral proteins that were prepared from the hr, LDH activity in culture fluid was measured with the
lysate of JE virus-infected cells as previously described Cytotoxicity Detection Kit (LDH) (Boehringer-Manheim
(Konishi et al., 1991). Corp., Indianapolis, IN). Percentage cytotoxicity was cal-
culated following the formula described in the manufac-
Proliferation assays of spleen cells
turer’s instructions.
In assays using radioisotopes, cells stimulated withViral antigens used in proliferation assays were the
live JE virus, fixed lysates of infected cells, and their the live antigen were washed three times with RPMI–
10% FBS and distributed in microplates. The target cellscontrols, which were prepared as previously described
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FIG. 1. JE virus-specific reactivity of sera obtained from mice inoculated with indicated immunogens. Sera were pooled from two mice, except
for one mouse immunized with JE virus. These specimens were tested for NEUT antibody and for their ability to immunoprecipitate radiolabeled
proteins harvested from JE virus-infected cells. NEUT antibody titers were represented as serum dilution yielding a 90% reduction in plaque number.
The positions of JE virus proteins are shown at the left side of the autoradiogram: E, envelope protein; NS1, nonstructural 1 protein; NS1*, a higher
molecular weight form of NS1 produced by alternative processing of the sequences encoded by the NS2A region of the JE virus genome (21).
used for this assay system were P815 mastocytoma cells washed with RPMI–10% FBS, resuspended at 5 1 106
cells per milliliter in each antibody dilution, and incu-infected with vP555 or vP410 at a m.o.i. of 10 or mock-
infected 15 to 20 hr before the assay. For target protein bated at 47 for 30 min. These cells were then treated
with rabbit complement (provided by Dr. Raymond Welsh)analysis, P815 cells infected with vP658, vP829, and
vP857 were also used. These target cells were labeled at 1:10 dilution at 377 for 1 hr and used for proliferation
or CTL assays. Controls were obtained with cells treatedwith Na 51CrO4 , washed three times with RPMI–10% FBS,
counted for viable cells, and distributed at 1 1 103 cells only with complement.
per well into microplates containing effector cells. The
plates were incubated for 4 to 6 hr at 377, and 51Cr release
RESULTSinto the supernatant was measured in a gamma counter.
Percentage specific lysis was calculated by a formula:
Induction of JE virus-specific antibodies
1001 (experimental release 0 minimum release)/(maxi-
mum release 0 minimum release), where the maximum In order to determine whether JE virus-specific anti-
release was obtained by lysing all the target cells with bodies were induced by immunization with recombinant
polyoxyethylene(12)tridecyl ether (Renex; Ruger Chemi- JE vaccine candidates, serum specimens were collected
cal Co., Irvington, NJ) at a final dilution of 1:40 and the from groups of two mice inoculated once or twice with
minimum release was obtained with target cells incu- JE virus, vaccine candidates (NYVAC-JEV and ALVAC-
bated alone in RPMI–10% FBS. JEV) or their controls (PBS, NYVAC, and ALVAC) 3 weeks
Under these conditions, the proportion of target cells after the last inoculation. The serum specimens from
expressing viral antigens was 50–60% in PMK cells in- each of two mice in the groups were pooled and tested
fected with JE virus and 40–50% in P815 cells infected for NEUT antibodies and for their ability to immunoprecip-
with vP555, as determined by an indirect fluorescent anti- itate radiolabeled E and NS1 (Fig. 1). Mice immunized
body assay using a monoclonal antibody to the JE virus E with NYVAC-JEV had higher NEUT antibody titers than
protein (J3-11B9) (Mason et al., 1991). P815 cells were mice immunized with ALVAC-JEV. Two inoculations elic-
resistant to infection with JE virus and showed 2–3% fluo- ited higher NEUT titers than single inoculations for both
rescent positive cells even after infection at a high m.o.i. recombinants. Half of the mice infected with JE virus died
in approximately 1 week, indicating that the dose used
Cell depletion assays
for immunization (1 1 107 PFU) was roughly the 50%
lethal dose.Cell depletion tests were performed using antibodies
to CD3 (anti-Thy1.2), CD4 (anti-L3T4, Becton Dickinson The results of RIP indicate that antibodies to E and
NS1 were induced in mice by immunization with JE virus,and Co., Mountain View, CA), CD8 (anti-Lyt2, Cedarlane
Laboratories, Ontario, Canada), and natural killer (NK) NYVAC-JEV, and ALVAC-JEV. Although antibody re-
sponses to NS1 were not observed in mice that receivedcells (anti-Asialo GM1 provided by Dr. Raymond Welsh,
University of Massachusetts Medical Center). The ascitic one inoculation with the recombinant viruses, faint but
obvious bands were observed after two inoculations. An-fluid-products (anti-CD3, anti-CD4, and anti-NK) were
used at a 1:100 dilution and the ammonium sulfate-con- tibody responses to E, demonstrated by RIP, were con-
sistent with results of the NEUT test. These results dem-centrate from culture fluids of hybridoma cultures (anti-
CD8) at 1:5. Cells stimulated with viral antigens were onstrate that immunization with recombinant JE vaccine
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TABLE 1
Proliferative Responses of Mouse Spleen Cells to Fixed and Live Antigens
Stimulation index a
Fixed antigenb Live antigenc
Number of
Experimentd inoculations Immunogene 1:200 f 1:2000 1:64 1:256
Exp. 1 1g JE virus 3.5 3.5 1.1 1.4
PBS 1.0 1.0 1.1 0.2
NYVAC-JEV 1.7 3.2 3.1 2.1
NYVAC 1.5 0.9 0.8 1.6
ALVAC-JEV 1.2 2.0 0.8 1.3
ALVAC 0.8 1.5 0.9 1.5
Exp. 2 1h JE virus 34.1 5.8 6.7 1.8
PBS 1.4 1.6 1.8 0.9
2i NYVAC-JEV 1.4 3.7 4.0 2.8
NYVAC 1.1 1.1 1.9 0.6
ALVAC-JEV 1.9 1.5 2.1 1.4
ALVAC 1.6 1.9 1.0 0.9
a Underlined values indicate significant levels of proliferation.
b Glutaraldehyde-fixed lysate of infected Vero cells.
c Culture fluid of infected C6/36 cells.
d In experiment 1, 4 1 105 spleen cells were cultured with indicated dilutions of stimulating antigens in 100 ml of RPMI 1640 medium containing
1% normal mouse serum (RPMI –1% NMS) for 3 days, and the culture was mixed with 100 ml of RPMI–5% FBS. Then, 100 ml of this mixture was
transferred into another microplate containing 100 ml of RPMI–5% FBS and further incubated at 377 for 2 days. In experiment 2, 2 1 105 spleen
cells were cultured with antigens in 100 ml of RPMI–1% NMS for 3 days, mixed with 100 ml of RPMI–10% FBS, and further incubated for 2 days.
e Groups of two mice were inoculated with indicated immunogens, except for one mouse immunized with JE virus.
f Dilution of stimulating antigen.
g Spleens were collected from mice 3 weeks postimmunization.
h Spleens were collected from mice 6 weeks postimmunization.
i Mice received two inoculations at an interval of 3 weeks, and 3 weeks later spleens were collected from immunized mice.
candidates induced NEUT antibody and antibodies to E the live antigens. A cell depletion test using spleen cells
obtained from a mouse that received one inoculationand NS1 in mice.
with JE virus and a mouse that received two inoculations
with NYVAC-JEV showed that proliferative responsesInduction of JE virus-specific T lymphocytes
against the live virus antigen were greatly reduced
In order to detect JE virus-specific T cell responses, (90%) by pretreatment with anti-CD3 and complement
spleen cells were collected from the mice that were used (data not shown). Spleen cells obtained from mice immu-
for antibody analyses and were examined for proliferative nized with either of the recombinant viruses were in-
responses against JE viral antigens (Table 1). In experi- duced to proliferate in response to stimulation with the
ment 1 we used mice that received one inoculation with fixed lysates of cells infected with either of the parent
each of six immunogens, and in experiment 2 we used viruses, NYVAC or ALVAC (data not shown). These re-
mice that received one inoculation with JE virus or PBS sults demonstrate that immunization with recombinant
and mice that received two inoculations with each of JE vaccine candidates induced JE virus-specific T lym-
another four immunogens. Spleen cells from mice immu- phocytes that proliferate by stimulation with the fixed
nized with JE virus or recombinant vaccine candidates and/or live JE antigens.
showed positive proliferative responses to JE antigens,
Duration of JE virus-specific memory T cellsbut spleen cells from those immunized with control
immunogens, PBS, NYVAC, or ALVAC did not. Stimu- The levels of specific antibody and memory T lympho-
cytes were examined in mice inoculated twice with re-lation indices obtained with ALVAC-JEV-immunized mice
were generally lower than those obtained with JE virus- combinant JE vaccine candidates at 1, 2, 4, and 6 months
after the second inoculation (Table 2). NYVAC-JEV-immu-and NYVAC-JEV-immunized mice. ALVAC-JEV-immunized
mice showed positive responses only against the fixed nized mice maintained detectable levels of NEUT anti-
body and JE virus-specific memory T cells for at least 6antigen after one inoculation. On the other hand, mice
that received one inoculation with JE virus and those months. ALVAC-JEV-immunized mice, on the other hand,
maintained detectable levels of NEUT antibody andwhich received one or two inoculations with NYVAC-JEV
showed positive responses against both the fixed and memory T cells for 4 months.
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TABLE 2
Duration of Immune Responses in Mice Inoculated with Recombinant JE Vaccine Candidates
Stimulation indexa
Fixed antigenb Live antigenc
Immunogend Monthe NEUT titer f 1:20 g 1:200 1:16 1:64
NYVAC-JEV 1 1:20 2.2 3.1 3.6 4.0
2 1:40 1.5 3.5 3.2 2.6
4 1:80 4.1 5.0 1.6 3.2
6 1:10 2.7 2.8 1.8 1.8
ALVAC-JEV 1 1:10 1.7 2.2 2.0 2.0
2 1:10 1.2 1.1 1.4 1.1
4 1:20 1.0 2.8 0.8 1.7
6 1:10 1.7 1.7 1.1 1.3
a Proliferation assay was performed with 2 1 105 spleen cells, which were cultured with antigens in 100 ml of RPMI–1% NMS for 3 days, mixed
with 100 ml of RPMI–10% FBS, and further incubated for 2 days. Underlined values indicate significant levels of proliferation.
b Glutaraldehyde-fixed lysate of infected Vero cells.
c Culture fluid of infected C6/36 cells.
d Groups of two mice received two inoculations with immunogens at a dose of 1 1 107 PFU at an interval of 2 weeks.
e Serum and spleen samples were collected from immunized mice at indicated months after the last inoculation.
f Serum dilution yielding a 90% reduction in plaque number. Pooled sera were used for the assay.
g Dilution of stimulating antigen.
Characterization of CTLs mock-infected PMK cells after in vitro stimulation with JE
virus. This result suggests that the spleen cells of JE
In order to elucidate the functions of specific T lympho-
virus-infected mice contained JE virus-specific memory
cytes, we examined cytotoxic activity of spleen cells after
CTLs. Similarly, spleen cells obtained from mice immu-
stimulation with the live antigen in vitro. Cytotoxic activity
nized with recombinant vaccine candidates showed highagainst JE virus-infected cells was first measured using
percentages of specific lysis against JE virus-infectedPMK cells as a target and LDH as a marker of cell lysis
PMK cells but not against mock-infected PMK cells.(Fig. 2). Spleen cells obtained from a JE virus-infected
Spleen cells stimulated with mock virus in vitro did notmouse lysed JE virus-infected PMK cells, but did not lyse
lyse infected or noninfected PMK cells. The levels of
specific lysis were similar for immunization with NYVAC-
JEV and immunization with ALVAC-JEV. These results
demonstrate that immunization with the recombinant vac-
cine candidates induced JE virus-specific memory cyto-
toxic cells.
Cytotoxic activities were also tested in another assay
system using P815 cells and 51Cr release (Fig. 3). At all
E:T ratios of 300:1, 100:1, and 33:1, spleen cells stimu-
lated with JE virus showed high percentages of specific
lysis against P815 cells infected with vP555 but did not
lyse vP410-infected or mock-infected P815 cells. Spleen
cells stimulated with mock antigen did not show cytotoxic
activity. These results are consistent with those shown
in Fig. 2, indicating that NYVAC-JEV and ALVAC-JEV in-
duce JE virus-specific CTLs in mice.
Cells demonstrating cytotoxic activities were exam-
ined for their phenotype by cell depletion tests. SpleenFIG. 2. Lysis of JE virus-infected PMK cells by JE virus-, NYVAC-JEV-,
cells collected from mice immunized with recombinantor ALVAC-JEV-immune spleen cells stimulated with JE virus. Mice were
immunized with one inoculation with JE virus or two inoculations of vaccines were stimulated with JE virus for 7 days in vitro,
NYVAC-JEV or ALVAC-JEV at an interval of 2 weeks. The dose of the and then treated with antibodies against surface cell
immunogen was 1 1 107 PFU. Six weeks postimmunization, the spleen markers and complement (Fig. 4). Cytotoxic activitiescells were harvested and incubated with a 1:8 dilution of the live antigen
were reduced by treatment with anti-CD3 and anti-CD8for 7 days. Cytotoxic activity was measured using LDH as a marker of
cell lysis (see Materials and Methods for details). antibodies, whereas activities were not reduced after
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FIG. 3. Lysis of P815 cells infected with a recombinant encoding the
prM, E, and NS1 genes (vP555), the parent virus (vP410), or the mock.
Mice were immunized with two inoculations of NYVAC-JEV or ALVAC-
JEV at an interval of 2 weeks. Six weeks postimmunization, the spleen
FIG. 5. Target antigen analysis of CTLs. Mice were immunized withcells were harvested and incubated with a 1:8 dilution of the live antigen
two inoculations of NYVAC-JEV or ALVAC-JEV at an interval of 2 weeks.for 6 days. Cytotoxic activity was measured using 51Cr as a marker of
Six weeks later, the spleen cells were harvested and incubated withcell lysis (see Materials and Methods for details).
a 1:8 dilution of the live antigen for 8 days. Cytotoxic activity was
measured using 51Cr-labeled P815 cells infected with vaccinia recombi-
treatment with anti-CD4. These results demonstrate that nants encoding prM, E, and NS1 (vP555), E and NS1 (vP658), prM and
E (vP829), NS1 (vP857), or no antigens (the parent virus; vP410).CD8/ T lymphocytes played a role in lysing vP555-in-
fected P815 cells. Since treatment with complement and
anti-NK antibody also reduced cytotoxic activity, it is likely
activities obtained with vP658-infected cells than thosethat NK cells also contributed to the cytotoxic activity
obtained with vP555-infected cells suggested that someobserved in these spleen cells.
CTLs in these populations recognized prM.Next we determined which JE virus proteins were rec-
ognized by the CD8/ CTLs by using P815 cells infected
DISCUSSIONwith recombinant vaccinia viruses encoding different JE
virus antigens (Fig. 5). Specific cytotoxic activities were This paper describes the induction of humoral and
observed against target cells infected with vP555 ex- cellular immunity in mice by poxvirus-vectored recombi-
pressing prM, E, and NS1, vP658 expressing E and NS1, nant JE vaccine candidates, NYVAC-JEV and ALVAC-JEV.
and vP829 expressing prM and E. On the other hand, no As we have shown in earlier studies (Mason et al., 1991;
activities were noted against P815 cells infected with Konishi and Mason, 1993), the recombinant viruses en-
vP857 expressing NS1 alone. These results indicate that coding the prM, E, and NS1 genes have the ability to
the predominant CTLs in these populations recognized express these proteins properly in infected cells, and
E. Although we have no direct evidence, lower cytotoxic these proteins are released from infected cells in a glyco-
sylated form. In particular, prM/M and E appear as subvi-
ral particles, suggesting that the synthesis of prM/M and
E proteins in the cells infected with recombinant viruses
are the same as in JE virus-infected cells. Therefore,
it is likely that immunization with these recombinants
induces immune responses identical to those induced
by JE virus infection. In this study, we demonstrated the
induction of specific CTLs as well as antibodies in mice
immunized with recombinant JE vaccine candidates and
in JE virus-infected mice.
Viral peptides which are prepared in the cytoplasm
are presented by MHC class I molecules on the surface
of infected cells and induce CD8/ CTLs (Germain, 1993).
Therefore, live recombinant viruses that can express for-
eign genes in the cytoplasm of infected cells are likely
FIG. 4. Phenotypic analysis of CTLs by cell depletion with indicated to induce CD8/ CTLs in immunized hosts. The induction
antibodies and complement. Mice were immunized with two inocula- of CTLs by recombinant viruses has been reported in
tions of NYVAC-JEV or ALVAC-JEV at an interval of 2 weeks. Six weeks humans with ALVAC-based human immunodeficiency vi-
later, the spleen cells were harvested and incubated with a 1:8 dilution
rus type 1 (HIV-1) (Egan et al., 1995; Pialoux et al., 1995)of the live antigen for 7 days. After cell depletion (see Materials and
and vaccinia virus-based HIV-1 (Perales et al., 1995) andMethods for details), cytotoxic activities were measured using 51Cr-
labeled P815 cells infected with vP555. in mice with Mengo virus-based HIV-1 (Altmeyer et al.,
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0020), the National Science Foundation (DMB 8515345), and the Minis-1994), vaccinia virus-based influenza virus (Sutter et al.,
try of Education, Science, Sports and Culture of Japan (Grant-in-Aid for1994), vaccinia virus-based respiratory syncytial virus
Scientific Research 06670328).
(Kulkarni et al., 1995), adenovirus-based measles virus
(Fooks et al., 1995), and vaccinia virus-based hepatitis B REFERENCES
virus (Schirmbeck et al., 1995). Consistent with the pres- Altmeyer, R., Escriou, N., Girard, M., Palmenberg, A., and van der Werf,
ent result in mice, we also demonstrated the induction S. (1994). Attenuated Mengo virus as a vector for immunogenic hu-
man immunodeficiency virus type 1 glycoprotein 120. Proc. Natl.of JE virus-specific human CTLs by immunization with
Acad. Sci. USA 91, 9775–9779.NYVAC-JEV and with ALVAC-JEV in a phase I human trial
Andersen, M. M., and Ronne, T. (1991). Side-effects with Japanese en-(Konishi et al., in preparation).
cephalitis vaccine. Lancet 337, 1044.
The titers of NEUT antibody and T-cell proliferative Brandt, W. E. (1988). Current approaches to the development of dengue
responses after immunization with NYVAC-JEV or AL- vaccines and related aspects of the molecular biology of flaviviruses.
J. Infect. Dis. 157, 1105–1111.VAC-JEV suggest that NYVAC-JEV is more immunogenic
Bukowski, J. F., Kurane, I., Lai, C.-J., Bray, M., Falgout, B., and Ennis, F. A.than ALVAC-JEV at the same infectious dose. Along with
(1989). Dengue virus-specific cross-reactive CD8/ human cytotoxic Tthis difference, NYVAC-JEV induced immune responses
lymphocytes. J. Virol. 63, 5086–5091.
which lasted longer compared to ALVAC-JEV. The levels Egan, M. A., Pavlat, W. A., Tartaglia, J., Paoletti, E., Weinhold, K. J., Clem-
of specific antibody and memory T lymphocytes were ents, M. L., and Siliciano, R. F. (1995). Induction of human immunode-
ficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte re-also higher with NYVAC-JEV than with ALVAC-JEV in hu-
sponses in seronegative adults by a nonreplicating, host-range-re-mans (Kanesa-Thasan et al., in preparation). Since the
stricted canarypox vector (ALVAC) carrying the HIV-1MN env gene.same cassette containing the promoter and JE virus
J. Infect. Dis. 171, 1623–1627.
genes was used in both recombinant poxviruses, the Fooks, A. R., Schadeck, E., Liebert, U. G., Dowsett, A. B., Rima, B. K.,
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